- |||||||||| CFT8634 / C4 Therap
CFT8634, a BRD9 BiDAC (Section 30) - Mar 5, 2024 - Abstract #AACR2024AACR_8180;
CFT8634 demonstrates synergy with dexamethasone in the RPMI-8226 in vivo xenograft model. This combination leads to tumor regressions at clinically relevant doses and outperforms the current combination of pomalidomide with dexamethasone.In conclusion, we demonstrate in vitro and in vivo activity in an expanded set of MM models using the clinical oral BRD9 degrader CFT8634 as a single agent and show in vivo synergy between CFT8634 and SoC agents pomalidomide and dexamethasone at clinically relevant doses.
- |||||||||| CFT8634 / C4 Therap
Trial termination, Metastases: CFT8634-1101: A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors (clinicaltrials.gov) - Jan 18, 2024
P1/2, N=50, Terminated,
This combination leads to tumor regressions at clinically relevant doses and outperforms the current combination of pomalidomide with dexamethasone.In conclusion, we demonstrate in vitro and in vivo activity in an expanded set of MM models using the clinical oral BRD9 degrader CFT8634 as a single agent and show in vivo synergy between CFT8634 and SoC agents pomalidomide and dexamethasone at clinically relevant doses. Active, not recruiting --> Terminated; High levels of BRD9 degradation did not result in sufficient efficacy in heavily pre-treated synovial sarcoma and SMARCB1-null solid tumor patients treated with CFT8634 as a single agent.
- |||||||||| CFT8634 / C4 Therap
Enrollment closed, Enrollment change, Metastases: CFT8634-1101: A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors (clinicaltrials.gov) - Nov 13, 2023
P1/2, N=50, Active, not recruiting,
Active, not recruiting --> Terminated; High levels of BRD9 degradation did not result in sufficient efficacy in heavily pre-treated synovial sarcoma and SMARCB1-null solid tumor patients treated with CFT8634 as a single agent. Recruiting --> Active, not recruiting | N=110 --> 50
|
